Figure 5.

IN10018 enhances the antitumor efficacy of Enhertu in human PDX models

(A–B) The tumor growth curves and body weight changes for the efficacy study with NSCLC PDX model LU-01-1626. IN10018 was dosed to the model once daily by oral gavage. For day 0 to day 3, the dose was 25 mg/kg. Since day 4, the dose of IN10018 was adjusted to 12.5 mg/kg via oral gavage. Enhertu was dosed once weekly by tail vein injection. The dose was set as 10 mg/kg in week 1, 3 mg/kg in week 2, and adjusted to 6 mg/kg from week 3 till the end of the study. Scale bar: 100 μm.

(C) The representative images of the IHC staining with anti-FAP, anti-human IgG, anti-DXD, anti-Ki67, and TUNEL assay for the tumors from the LU-01-1626 model.

(D–F) The FAP-positive cells, anti-human immunoglobulin G (IgG)-positive cells, and anti-DXD-positive cells per unit area of the tumors from LU-01-1626 model.

(G–H) The Ki67 and TUNEL staining analysis of the tumors from LU-01-1626 model. The data from pathological assays were analyzed by ImageJ. Data represent mean ± SEM. The unpaired student’s t test was used for the statistical analysis. ∗p < 0.05, ∗∗p < 0.01. Scale bar: 50 μm.